Click here to go to the previous page
Lipid Management Cases by the Guidelines or by Common Sense?
Program Code:
CMF15
Date:
Tuesday, June 7, 2011
Time:
2:45 PM to 3:05 PM
EST
SPEAKER
(S):
Kenneth Feingold, MD, VAMC
Disclosures: KF: Speaker, Abbott Laboratories, Merck & Co., Takeda; Principal Investigator, Merck & Co.
|
Dr. Tannock is Chief of the Division of Endocrinology and Molecular Medicine at the University of Kentucky, and Associate Director of the Barnstable Brown Kentucky Diabetes and Obesity Center. She is a physician-scientist who divides her time between clinical activities and research. She obtained her MD and Internal Medicine training at the University of Toronto, Canada, then completed a fellowship in Metabolism, Endocrinology and Nutrition at the University of Washington. Dr. Tannock was recruited to the University of Kentucky in January 2004. In addition to her academic responsibilities, she is an Associate Editor for the journals “Atherosclerosis” and “Postgraduate Medicine”. Dr. Tannock specializes in the treatment of patients with metabolic syndrome, diabetes, and dyslipidemias. She has a particular interest in the management of highly insulin resistant diabetes, and patients at high risk for cardiovascular diseases. Her research aims to understand the mechanisms leading to the increased risk of cardiovascular disease in such individuals, with a focus on understanding the mechanisms leading to lipid deposition within the artery wall. She has research support from the National Institutes of Health and the Veterans Affairs Research Program.
|